



SATELLITE SYMPOSIUM SUPPORTED BY NOVARTIS

16:15 – 18:15

Hall A2

**TKIs IN CML: SAME TARGET, NEW POWER
ADDRESSING THE SPECTRUM OF BCR-ABL PATHOLOGY**

Chair: H Kantarjian (M.D. Anderson Cancer Center, Houston, USA)

16:15 - 16:30

■ **CML THERAPY – CAN PATIENTS ANTICIPATE
A NORMAL LIFE EXPECTANCY?**

G Saglio (Università degli Studi di Torino, Torino, Italy)

16:30 - 16:45

■ **IMATINIB DOSE OPTIMISATION**

T Hughes (Royal Adelaide Hospital, Adelaide, Australia)

16:45 - 16:55

■ **CLINICAL CASE AND PANEL DISCUSSION: OVERCOMING
SUB-OPTIMAL RESPONSE WITH INCREASED IMATINIB DOSE**

H Kantarjian (M.D. Anderson Cancer Center, Houston, USA)

16:55 - 17:15

■ **NILOTINIB: RE-TARGETING IMATINIB-RESISTANT PATIENTS**

O Ottmann (Universitätsklinik Frankfurt, Frankfurt, Germany)

17:15 - 17:30

■ **INTEGRATED MANAGEMENT OF CML IN
THE ERA OF 2ND-GENERATION TKIs**

K Porkka (Helsinki University Central Hospital, Helsinki, Finland)

17:30 - 17:40

■ **QUESTION AND ANSWER SESSION**

H Kantarjian (M.D. Anderson Cancer Center, Houston, USA)

17:40 - 17:55

■ **CML THERAPIES IN EVOLUTION – WHAT DOES THE FUTURE HOLD?**

A Hochhaus (University of Heidelberg, Mannheim, Germany)

17:55 - 18:10

■ **2ND GENERATION TKIs – PUTTING THEM IN PERSPECTIVE IN 2008**

H Kantarjian (M.D. Anderson Cancer Center, Houston, USA)

18:10 - 18:15

■ **CLOSING REMARKS**